Hypothesis Berberine’s neuroprotective effects in aging arise not from direct neuronal AMPK activation but from a gut‑brain cascade: berberine reshapes the colonic microbiota, increasing production of secondary bile acids (e.g., deoxycholic acid, lithocholic acid) that activate vagal afferent TGR5 receptors. This vagal signal triggers CREB‑dependent BDNF expression in the hippocampus and cortex, thereby reducing neuroinflammation and preserving cognitive function.

Rationale

• Berberine markedly alters gut microbiome composition, boosting bile‑acid‑transforming bacteria (e.g., Clostridium scindens)【https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.764994/full】.
• Secondary bile acids are potent agonists of TGR5, a G‑protein‑coupled receptor expressed on vagal afferents【https://pubmed.ncbi.nlm.nih.gov/27887947/】.
• Vagal TGR5 signaling elevates intracellular cAMP, activating PKA and CREB, which drives BDNF transcription【https://www.aging-us.com/article/100593/text】.
• BDNF supports neuronal survival, synaptic plasticity, and dampens microglial activation, key factors in age‑related cognitive decline【https://pmc.ncbi.nlm.nih.gov/articles/PMC11438515/】.
• Direct neuronal AMPK activation by berberine is limited by poor blood‑brain barrier permeability; yet systemic berberine improves cognition in aged mice, suggesting an indirect route【https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059038/】.

Predictions

1. Vagotomy will abolish berberine‑induced increases in hippocampal BDNF and the accompanying cognitive improvement in aged mice.
2. Genetic deletion of TGR5 specifically in vagal sensory neurons will phenocopy the vagotomy effect, despite intact gut microbiome changes.
3. Colonization of germ‑aged mice with microbiota from berberine‑treated donors will elevate circulating secondary bile acids, activate vagal TGR5 signaling, raise BDNF, and rescue memory deficits without berberine administration.
4. Pharmacological blockade of TGR5 (e.g., with SBP‑0636457) will prevent berberine‑mediated BDNF upregulation and neuroprotection.

Experimental Approach

• Model: 20‑month‑old C57BL/6 mice randomized to berberine (200 mg/kg/day oral) or vehicle for 8 weeks.
• Groups: (i) sham + berberine, (ii) subdiaphragmatic vagotomy + berberine, (iii) vagal‑neuron‑specific Tgr5 floxed crossed with Advillin‑Cre + berberine, (iv) germ‑aged recipients of feces from berberine‑treated donors, (v) berberine + TGR5 antagonist.
• Readouts: fecal bile‑acid profiling (LC‑MS), vagal afferent cAMP/PKA activity (ex vivo electrophysiology), hippocampal BDNF mRNA/protein (qPCR, Western blot), microglial activation (Iba1 immunohistochemistry), Morris water maze performance, and plasma LPS/LBP as inflammation markers.
• Controls: verify that berberine still alters microbiome and reduces peripheral lipids in all groups to isolate the gut‑brain axis.

Potential Outcomes

• If vagal TGR5 signaling is necessary, groups (ii)–(iv) will show no BDNF rise or cognitive benefit despite microbiome remodeling and reduced peripheral inflammation.
• If sufficient, microbiota transfer alone (group iv) will mimic berberine’s central effects.
• Antagonist treatment (group v) will block BDNF increase, confirming receptor specificity.

Implications Confirming this mechanism would re‑position berberine (and similar AMPK activators) as a modulator of the gut‑brain axis rather than a direct neuro‑drug. It would highlight bile‑acid‑mediated vagal signaling as a therapeutic lever for age‑related cognitive decline, encouraging microbiome‑targeted interventions or TGR5 agonists that bypass the need for systemic drug exposure.